Elevance Health (NYSE:ELV) Issues Quarterly Earnings Results

Elevance Health (NYSE:ELV) posted its quarterly earnings results on Wednesday. The company reported $12.58 EPS for the quarter, topping the consensus estimate of $10.74 by $1.84, Zacks reports. Elevance Health had a net margin of 2.84% and a return on equity of 15.59%. The company had revenue of $49.49 billion during the quarter, compared to analysts’ expectations of $48.21 billion. During the same quarter in the previous year, the business posted $11.97 EPS. The firm’s revenue was up 1.5% on a year-over-year basis. Elevance Health updated its FY 2026 guidance to 19.850- EPS.

Here are the key takeaways from Elevance Health’s conference call:

• Q1 adjusted diluted EPS of $12.58 beat expectations and management raised full?year adjusted EPS guidance to at least $26.75, noting ~$1 per share of non?recurring net investment income helped results.
• Management recorded a $935 million accrual tied to historical CMS risk?adjustment data and is working with the agency toward resolution; they say it doesn’t change the outlook but it is a material contingent exposure.
• Company initiatives—leadership realignment, scaling AI (>$1 billion in digital/AI investments), and integrating Carelon/CareBridge—are cited as drivers of efficiency and demand, with reported benefits like ~20% lower readmissions and >10% savings on post?acute care.
• Membership and segment cadence: total members rose to 45.4 million; Medicare performance is improving (targeting ?2% operating margin for 2026), Medicaid faces planned high?single?digit membership declines and is seen as a 2026 trough, while ACA enrollment grew with a bronze?plan mix causing seasonality.

Elevance Health Stock Performance

Shares of ELV opened at $337.47 on Thursday. The stock has a market capitalization of $74.13 billion, a P/E ratio of 13.51, a P/E/G ratio of 1.81 and a beta of 0.49. The company has a debt-to-equity ratio of 0.70, a quick ratio of 1.54 and a current ratio of 1.54. Elevance Health has a 1 year low of $273.71 and a 1 year high of $429.25. The company’s fifty day moving average is $308.80 and its two-hundred day moving average is $331.56.

Elevance Health Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, June 25th. Shareholders of record on Wednesday, June 10th will be paid a $1.72 dividend. This represents a $6.88 annualized dividend and a yield of 2.0%. The ex-dividend date of this dividend is Wednesday, June 10th. Elevance Health’s payout ratio is currently 27.39%.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in ELV. Pettinga Financial Advisors LLC raised its holdings in Elevance Health by 4.8% during the fourth quarter. Pettinga Financial Advisors LLC now owns 812 shares of the company’s stock worth $285,000 after purchasing an additional 37 shares in the last quarter. Foresight Global Investors Inc. raised its stake in shares of Elevance Health by 5.6% during the 4th quarter. Foresight Global Investors Inc. now owns 865 shares of the company’s stock worth $303,000 after buying an additional 46 shares in the last quarter. UMB Bank n.a. lifted its holdings in shares of Elevance Health by 2.6% in the 4th quarter. UMB Bank n.a. now owns 2,113 shares of the company’s stock valued at $741,000 after buying an additional 53 shares during the period. HM Payson & Co. raised its position in Elevance Health by 15.0% in the fourth quarter. HM Payson & Co. now owns 437 shares of the company’s stock worth $153,000 after acquiring an additional 57 shares in the last quarter. Finally, CreativeOne Wealth LLC lifted its holdings in Elevance Health by 4.4% in the third quarter. CreativeOne Wealth LLC now owns 1,569 shares of the company’s stock valued at $507,000 after acquiring an additional 66 shares during the period. 89.24% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several equities analysts recently commented on the company. Truist Financial dropped their target price on Elevance Health from $390.00 to $375.00 and set a “buy” rating on the stock in a report on Monday, April 13th. Barclays cut their price target on shares of Elevance Health from $404.00 to $393.00 and set an “overweight” rating on the stock in a research note on Friday, January 30th. Sanford C. Bernstein reduced their price objective on Elevance Health from $431.00 to $409.00 and set an “outperform” rating for the company in a research note on Friday, January 30th. Jefferies Financial Group decreased their price objective on Elevance Health from $395.00 to $391.00 and set a “buy” rating for the company in a report on Monday. Finally, UBS Group set a $400.00 price target on shares of Elevance Health in a research note on Thursday, January 29th. Eleven research analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $379.75.

Key Headlines Impacting Elevance Health

Here are the key news stories impacting Elevance Health this week:

• Positive Sentiment: Q1 beat and raised full?year outlook — ELV reported Q1 EPS of $12.58 vs. consensus ~ $10.7–$11.0 and revenue above expectations; management raised 2026 adjusted EPS guidance (now targeting at least $26.75) and signaled at?least 12% EPS growth target for 2027, supporting upside to earnings expectations. Elevance raises 2026 adjusted EPS outlook
• Positive Sentiment: Margin expansion and operating discipline — Company commentary and coverage highlight improved claims experience, operating discipline and AI integration as drivers of margin expansion that underpin the guidance raise. ELV Q1 deep dive
• Positive Sentiment: Investment income and cash return — Net investment income jumped (reported ~29.7% increase), helping offset membership pressures and higher medical costs; company also declared a $1.72 quarterly dividend (?2.1% yield), which supports income investors. Zacks: Beats on rising net investment income
• Neutral Sentiment: Analyst action mixed — Robert W. Baird raised its price target from $317 to $331 but maintained a “neutral” rating, implying limited near?term upside from current levels; other outlets note mixed valuation metrics after the quarter. Benzinga / The Fly: Baird raises PT to $331
• Negative Sentiment: Investor litigation investigation — Law firm Kirby McInerney opened an investigation into potential securities claims involving Elevance and senior management, which could raise legal/oversight risk and increase volatility while the matter develops. GlobeNewswire: Investor alert

Elevance Health Company Profile

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.